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Abstract
Peroxisome proliferator-activated receptord (PPARd) is a transcription factor that is associated with metabolic gene
regulation and inflammation. It has been implicated in tumor promotion and in the regulation of 3-phosphoinositide-
dependent kinase-1 (PDK1). PDK1 is a key regulator of the AGC protein kinase family, which includes the proto-oncogene
AKT/PKB implicated in several malignancies, including breast cancer. To assess the role of PDK1 in mammary tumorigenesis
and its interaction with PPARd, transgenic mice were generated in which PDK1 was expressed in mammary epithelium
under the control of the MMTV enhancer/promoter region. Transgene expression increased pT308AKT and pS9GSK3b, but
did not alter phosphorylation of mTOR, 4EBP1, ribosomal protein S6 and PKCa. The transgenic mammary gland also
expressed higher levels of PPARd and a gene expression profile resembling wild-type mice maintained on a diet containing
the PPARd agonist, GW501516. Both wild-type and transgenic mice treated with GW501516 exhibited accelerated rates of
tumor formation that were more pronounced in transgenic animals. GW501516 treatment was accompanied by a distinct
metabolic gene expression and metabolomic signature that was not present in untreated animals. GW501516-treated
transgenic mice expressed higher levels of fatty acid and phospholipid metabolites than treated wild-type mice, suggesting
the involvement of PDK1 in enhancing PPARd-driven energy metabolism. These results reveal that PPARd activation elicits a
distinct metabolic and metabolomic profile in tumors that is in part related to PDK1 and AKT signaling.
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Introduction
3-Phosphoinositide-dependant protein kinase-1 (PDK1) regu-
lates at least 23 members of the AGC protein kinase family,
including AKT, p70 ribosomal S6 kinase (S6K) and all isotypes of
the protein kinase C (PKC) family [1]. PDK1 primes AGC kinases
by phosphorylation of a highly conserved sequence within the T-
loop or activation loop [2,3]. Although, PDK1 is constitutively
active [4,5], its activity may be further enhanced by transphos-
phorylation on tyrosine and serine residues by other kinases.
PDK1 can also regulate cell signaling in other capacities, such as
serving as a nucleo-cytoplasmic shuttling protein [6], an activator
of RalGDS [7], recruiting PKCh and scaffold protein CARD11 to
lipid rafts [8], and as a co-activator of peroxisome proliferator-
activated receptorc (PPARc) in adipogenesis [9]. PDK1 plays an
important role in mediating the effects of insulin and growth
factors that regulate cell proliferation, cell size, differentiation and
survival [10]. While homozygous deletion of PDK1 is embryonic
lethal [10,11], hypomorphic mice with a 90% PDK1 deficiency
develop normally. In contrast, PDK1 expression and gene copy
number are increased in breast cancer [12,13,14] and breast
cancer cell lines [15], which is consistent with down-regulation of
PDK1 inhibiting cancer cell migration and metastases [16], and
over-expression of PDK1 inducing transformation, drug resis-
tance, invasion and tumorigenicity [13,17,18]. Thus, PDK1
appears to have diverse roles in both normal and malignant cells
through kinase-dependent and -independent mechanisms.
PPARs belong to the nuclear receptor superfamily of ligand-
dependent transcription factors, which control metabolic and
inflammatory signaling associated with diabetes and lipodystro-
phies [19], but also regulate genes associated with proliferation,
survival and angiogenesis in tumor cells [20,21,22]. Among the
three PPAR isotypes, PPARd is distinguished by its ability to
function as a promoter of tumorigenesis in many instances [21],
and is highly expressed in colon cancer [23,24], head and neck
cancer [25], endometrial cancer [26] and breast cancer [21].
PPARd activation promotes breast and prostate cancer cell growth
[20] and a more aggressive phenotype [27]. In lung cancer cells,
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activity and co-regulate their expression in concert with prolifer-
ation [28]. PPARd agonists accelerate mammary carcinogenesis
[29] and promote metastatic gastric tumorigenesis [30], whereas,
disruption of PPARd blocks mammary and colon tumorigenesis
[31,32], although studies to the contrary have been reported
[33,34]. The tumor promoting effects of PPARd may be related in
part to activation of PDK1, which is a PPARd target gene in
keratinocytes [35,36]. PDK1 and PPARd co-associate in DMBA-
induced mammary tumors [9,29], and PPARd activates PI3K/
PDK1 signaling in a diverse range of cell types to enhance survival
and growth [36,37,38]. Thus, there is evidence to suggest that
PDK1 and PPARd may act cooperatively in tumorigenesis.
The in vivo consequences of PDK1 transgene expression in the
mammary gland, its effect on tumorigenesis, and its influence on
the tumor promoting effects of PPARd activation have not been
investigated. To address these questions, transgenic mice were
generated that express PDK1 in the mammary gland under the
control of the mouse mammary tumor virus (MMTV) enhancer/
promoter sequence in the long terminal repeat. Here we report that
Figure 1. PDK1 transgene expression and analysis of downstream signaling. (A) PCR analysis. DNA was prepared from tail DNA and
transgene expression analyzed by PCR using primers specific for the MMTV-PDK1 transgene. The results indicate that MMTV-PDK1 is expressed in four
founder lines. (B) IHC analysis indicates that pS241PDK1, pT308AKT and PPARd were increased in the mammary gland of two nulliparous MMTV-PDK1
mice (+) vs. a wild-type littermate (2) from founder line 192. Magnification 6006. (C) Western analysis. Mammary gland lysates from two 7 week-old
nulliparous MMTV-PDK1 (+) mice and one wild-type (2) littermate derived from founder line 192 were analyzed by western blotting. Founder line 192
expressed increased pT308AKT, pS9GSK3b and PPARd. The bar graph represents quantitation of the western blots normalized to either non-
phosphorylated protein or bactin levels.
doi:10.1371/journal.pone.0016215.g001
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PPARd-like gene expression profile associated with glucose and
lipid metabolism. Treatment with the selective PPARd agonist
GW501516 markedly accelerated mammary carcinogenesis, par-
ticularly in MMTV-PDK1 mice, and the reduction in tumor
latency correlated with a metabolic gene expression and metabo-
lomic signature that differed from wild-type animals. These results
suggest that the tumor promoting effects of a PPARd agonist are
associated in part with PDK1 and a distinct metabolic profile
related to glycolysis utilization and lipid biosynthesis.
Materials and Methods
MMTV-PDK1 mice were generated by pronuclear injection of
FVB mouse embryos as previously described [39]. The N-terminal
Myc-tagged human PDK1 cDNA [4] was kindly provided by Dr.
Dario Alessi, University of Dundee, and cloned into the EcoR1 site in
the MMTV-SV40-Bssk vector provided by Dr. William Muller,
McMaster University, Hamilton, Ontario, Canada. The MMTV-
PDK1 construct was digested with Sal I-Spe I, purified and used for
microinjection. All animal studies were conducted under protocols 07-
017 and 09-061, ‘‘Chemopreventive agents in mammary progenitor
cell targeting in carcinogen-induced breast cancer’’, approved by the
Georgetown University Animal Care and Use Committee in
accordance with NIH guidelines for the ethical treatment of animals.
Genotyping
Primers designed to detect a fragment unique to the MMTV-
PDK1 transgene were: forward: 59 CGC CGC AGC CTC GGA
AGA AGC GGC, reverse: 59GGG TAC CTC ACT GCA CAG
CGG CGT CC. Mice were screened for transgene expression by
PCR using tail DNA.
Western blot analysis
Lysates were prepared from either tumor cell cultures or
mammary glands using a lysis buffer containing: 50 mM Tris-
Figure 2. GW501516 enhances DMBA-induced mammary carcinogenesis. (A) Following medroxyprogesterone/DMBA treatment, tumor
latency was similar between MMTV-PDK1 mice and wild-type littermates, but was reduced in both groups by treatment with the PPARd agonist
GW501516. Survival is defined as the time at which tumors reached ,1000 mm
3 and animals were euthanized. The median tumor-free interval (T50)
was 89 days for MMTV-PDK1 mice (PDK1) vs. 110 days for wild-type mice (WT) (P=0.1738); 54 days for GW501516-treated wild-type animals vs. 110
days for WT mice (P=0.0019); 21 days for GW501516-treated PDK1 mice vs. PDK1 mice (P=0.0002). Statistical analysis used the log rank test. The
number (N) of mice per group was: WT (N=10), WT+GW (N=10), PDK1 (N=8), PDK1+GW (N=6). (B) Cumulative mammary tumor formation. The total
number of tumors is expressed as a percentage of total tumor number. Percent tumor formation between GW501516-treated WT vs. WT mice
(P=0.0127), GW501516-treated PDK1 vs. PDK1 mice (P=0.0011) and GW501516-treated PDK1 vs. WT mice (P=0.0001 were statistically significant.
Tumor formation in WT vs. PDK1 mice (P=0.710) was not significantly different. (C) IHC analysis indicates that PDK1, pT308AKT and PPARd expression
are increased in two adenocarcinomas from MMTV-PDK1 mice (+) vs. an adenocarcinoma from a wild-type littermate (2). Magnification 6006. (D)
Immunoblot analysis indicates that PDK1 and pT308AKT are elevated in adenocarcinomas from MMTV-PDK1 mice (+) vs. wild-type mice (2), but were
unchanged in squamous carcinomas.
doi:10.1371/journal.pone.0016215.g002
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late, 125 mM NaCl, 1 mM EDTA, 50 mM NaF, 1 mM sodium
orthovanadate, 2.5 mM sodium pyrophosphate, 1 mM sodium b-
glycerophosphate, 1 mM PMSF, and a protease inhibitor cocktail
(Roche Molecular Biochemicals). Mammary tissue was snap-frozen
in liquid nitrogen and powdered in a mortar and pestle. Following
incubation on ice for 30 min, lysates were cleared by centrifugation
at 13,0006g for 15 min at 4uC. Protein concentration was
determined using the Coomassie Plus Protein Assay (Pierce), and
20–50 mg of lysate were separated in a 4–12% NuPAGE Bis-Tris
gel (Invitrogen). After wet transfer, membranes were blocked for
5 min at room temperature in 0.5% non-fat dry milk in Tris-
buffered saline containing 0.1% Tween-20. Primary antibody was
incubated for either 1.5 hr at room temperature or overnight at
4uC. Secondary antibody was incubated for 30 min at room
temperature, and proteins were visualized with West Pico Stable
(Pierce). Antibodies and their dilution were the following: AKT1
and PDK1 (1:2,000, Upstate Biotechnology), b-actin (1:5,000,
Sigma-Aldrich), pS241PDK1 and pS308AKT, PKCa and
pS657PKCa (1:1,000, Cell Signaling Technologies), PTEN
(1:1,000, Santa Cruz Biotechnology), PPARd (1:1,000, Zymed)
and horseradish peroxidase-conjugated anti-rabbit IgG and anti-
mouse IgG (1:5,000, Pierce).
Mammary carcinogenesis
DMBA (dimethylbenz(a)anthracene, Sigma) was dissolved in
cottonseed oil at a concentration of 10 mg/ml. MMTV-PDK1
mice and wild-type littermates from founder line 192 were
administered medroxyprogesterone/DMBA as previously de-
scribed [40]. Briefly, 5 week-old virgin female mice were injected
s.c. with 15 mg of medroxyprogesterone acetate suspension (Sicor
Pharmaceuticals, Inc.), and one week later were administered 4
weekly doses of 1 mg DMBA in 0.1 ml cottonseed oil by gavage. A
diet supplemented with 0.005% GW501516 was started one day
after the last dose of DMBA [29]. GW501516 was provided by the
Chemoprevention Branch, National Cancer Institute. Mice were
euthanized by carbon dioxide inhalation when tumors reached 1–
1.5 cm
3. All animal protocols were approved by the Georgetown
University Animal Care and Use Committee.
Histopathology
Tumor samples were dissected free of connective tissue and
fixed in formalin. Paraffin blocks were prepared for hematoxylin &
eosin (H&E) staining by the Histopathology and Tissue Shared
Resource, Lombardi Comprehensive Cancer Center (LCCC),
Georgetown University. Tumors were classified using the
histological nomenclature recommended by Cardiff et al. [41] as
adenocarcinomas, including acinar and solid lobular types,
adenosquamous and squamous carcinomas and myoepithelial
and undifferentiated carcinomas as previously described [40].
Immunohistochemistry
IHC analysis was carried out as previously described [29,39,40].
The following primary antibodies were: mouse anti-PDK1 (1:50,
sc-17765, Santa Cruz Biotechnology), rabbit anti-pT308AKT
(1:600, sc-16646, Santa Cruz Biotechnology), rabbit anti-PPARd
(1:200, sc-7197, Santa Cruz Biotechnology).
Gene Microarray
Mammary gland tissue was excised and preserved in RNAlater
(Ambion) at 220uC until RNA was extracted using an RNeasy
Mini Kit (Qiagen) according to the manufacturer’s protocol. RNA
purity was assessed by an A260/A280 ratio of $1.9, and RNA
quality was monitored using a microfluidic nanochip (Agilent).
cRNA synthesis was carried out using the Affymetrix protocol with
minor modifications as previously described [40]. Biotin-labeled
cRNA was fragmented at 94uC for 35 min and used for
hybridization overnight to an Affymetrix mouse 430A2.0 Gene-
ChipH by the Genomics and Epigenomics Shared Resource,
LCCC, Georgetown University. The GeneChipH was scanned
using an Agilent Gene Array scanner, and grid alignment and
raw data generation performed with the Affymetrix GeneChipH
Operating software 1.1. A noise value (Q) based on the variance
of low-intensity probe cells was used to calculate a minimum
threshold for each GeneChip. Data generated after scanning
was subjected to comparison analysis to select change calls at
100% increase or decrease compared with control for each gene.
Gene array analysis was further refined by evaluating differences
between paired samples and ranking changes by their log2 ratio.
Differences in signal ratio .log2 2.0 and ,log2 22.0 were ranked,
and genes with a signal of ,300 in all experimental groups
were excluded from analysis. Each cRNA was prepared from
equal amounts of RNA pooled from 5 mice per group.
Hierarchical clustering was carried out by standardizing trans-
formed log base 2 values from the raw intensities using the
equation Z~
X{m
s
, and multiplying by a constant to adjust all
values from 23t o+3. Euclidean distances, as described in
p{q kk ~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
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p
~
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2z q kk
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q
were used to
compute distances between genes as well as samples separately.
Finally the average linkage as DJM~
NKDJKzNLDJL
NM
was
applied to determine the gene clusters and sample clusters. All
data is MIAME compliant and the raw data has been deposited in
the GEO database.
Metabolomic analysis
Metabolomic analysis was performed using ultraperformance
liquid chromatography electrospray ionization time-of-flight mass
spectrometry (UPLC-ESI-TOFMS) [42] by the Proteomic and
Metabolomics Shared Resource, LCCC, Georgetown University.
Experimental groups consisted of mammary glands from each of
five control wild-type and transgenic littermates and an equal
number treated with GW501516 for seven days. Tissue was snap-
Table 1. Tumor histology and multiplicity.
% of each
histotype
Histopathology: WT WT+GW* PDK1 PDK1+GW**
Adenocarcinoma 57 13 34 0
Adenosquamous/squamous 29 80 33 91
Myoepithelial/undifferentiated 14 7 33 9
Tumor multiplicity 1.40 1.5 1.88 1.67
No. of tumors 14 15 15 10
No. of animals 10 10 8 6
*P=0.0125 vs. untreated WT mice for histological differences.
**P=0.0205 vs. untreated PDK1 mice for histological differences.
Wild-type (WT) and MMTV-PDK1 transgenic mice (PDK1) were fed either
standard rodent chow or chow supplemented with 0.005% (w/w) GW501516
(GW). GW501516 treatment produced a significant change in the percentage of
adenosquamous/squamous carcinomas. There were no significant differences
in tumor multiplicity between groups.
doi:10.1371/journal.pone.0016215.t001
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prepared in 50% methanol containing internal standards using
MagNAlyser Green Beads and a MagNA Lyser agitator (Roche).
Samples were clarified, and processing and multivariate analysis
performed as described [42]. Each sample (5 ml) was injected onto
a reverse-phase 5062.1 mm ACQUITYH 1.7-mm C18 column
(Waters Corp, Milford, MA) using an ACQUITYH UPLC system
(Waters) with a gradient mobile phase consisting of 2% acetonitrile
in water containing 0.1% formic acid (A) and 2% water in
acetonitrile containing 0.1% formic acid (B). Each sample was
resolved for 10 min at a flow rate of 0.5 ml/min. The gradient
consisted of 100% A for 0.5 min then a ramp of curve 6 to 100%
B from 0.5 min to 10 min. The column eluent was introduced
directly into the mass spectrometer by electrospray. Mass
spectrometry was performed on a Q-TOF PremierH (Waters)
operating in either negative-ion (ESI2) or positive-ion (ESI+)
electrospray ionization mode with a capillary voltage of 3200 V
and a sampling cone voltage of 20 V in negative mode and 35 V
in positive mode. The desolvation gas flow was set to 800 liters/h
and the temperature was set to 350uC. The cone gas flow was
25 liters/hr, and the source temperature was 120uC. Accurate
mass was maintained by introduction of LockSprayH interface of
sulfadimethoxine (311.0814 [M+H]
+ or 309.0658 [M2H]
2)a ta
concentration of 250 pg/ml in 50% aqueous acetonitrile and a rate
Figure 3. GW501516 increases PDK1, pT308AKT, PPARd and b-catenin expression in the mammary gland. (A) Immunoblot analysis of
mammary gland lysates from a wild-type (WT) and two MMTV-PDK1 (PDK1) mice maintained on either standard (2) or GW501516-supplemented (+)
diets. The results indicate that GW501516 increased PDK1 and pT308AKT in both groups, and pS9GSK3b in wild-type mice. (B) IHC analysis indicates
that PDK1, pT308AKT, PPARd and b-catenin were preferentially increased in wild-type mice following GW501516 treatment. Magnification 6006. (C)
Comma-1D mammary epithelial cells transduced with either empty virus (Control) or PDK1-expressing virus (PDK1), and assessed for PPARd
expression by western blotting. PDK1 cells transfected with PPARd (PDK1+PPARd) served as a positive control. PPARd expression was increased in
PDK1 cells. (D) Cells in (C) were examined for PPARd-dependent reporter gene activity in the presence and absence of GW501516 and dominant-
negative PPARd (DN-PPARd). PPARd-dependent was increased .10-fold in PDK1-expressing cells vs. control cells, and activity was suppressed by DN-
PPARd.
doi:10.1371/journal.pone.0016215.g003
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850 m/z in MS scanning. Centroided and integrated mass
spectrometry data from the UPLC-TOFMS were processed to
generate a multivariate data matrix using MarkerLynxH (Water)
that was used for analysis by SIMCA-P+11 software (Umetrics),
and classified with Random Forest. Principal components analysis
(PCA) and partial least-squares discrimination analysis (PLS-DA)
was performed on Pareto-scaled MarkerLynx matrices to identify
candidate metabolites that distinguished WT from transgenic
tissue, as well as tissues from animals treated with GW501516.
Metabolites were identified using the Madison Metabolomics
Database Consortium, Lipidmaps and Scripps Centre for Mass
Spectrometry, and negative-ion and positive-ion electrospray
mode. Metabolites were verified using tandem MS by comparison
to authentic compounds.
Cell culture and reporter gene analysis
Comma-1D/SRa and Comma-1D/PDK1 cells [15,43] were
grown in 24-well plates in DMEM medium containing 5% fetal
calf serum. After 24 hr, medium was replaced with DMEM-
containing 5% stripped FBS (Invitrogen). Cells were transfected
using Lipofectamine Plus (Invitrogen) and the reporter plasmids
pTopFlash (Invitrogen) or pGL2–3XPPRE–Luciferase reporter
plasmid (provided by Dr. Mitchell Lazar, University of Pennsyl-
vania) together with either control pcDNA3.1 or pcDNA3.1
expressing dominant-negative PPARd (mPPARdR112P) (Y. Yin
and R.I. Glazer, unpublished results). PPRE-luciferase activity was
measured in the presence of GW501516, and pTopFlash was used
to measure b-catenin/TCF-dependent transcription. Luciferase
activity was measured with the Dual-Luciferase assay system
(Promega, Madison, WI).
Statistical Analysis
Tumor survival data were assessed by Kaplan-Meier analysis by
the log rank test, and tumor number incidence by the Mann-
Whitney U test using GraphPad Prism version 4 (GraphPad
Software). Histological analysis of tumors was performed by Fishers’
Exact test. Differences were considered to be significant at P,0.05.
Results
MMTV-PDK1 transgenic mice
MMTV-PDK1 transgenic mice were screened for transgene
expression by PCR of tail DNA, and four founder lines were
identified (Figure 1A). Founder line 192 expressed 8–10-fold
higher pS241PDK1 and PDK1 levels vs. wild-type littermates,
compared to a 1.5–2-fold change in other founder lines (results not
shown), and thus, founder 192 was used for all subsequent studies.
Table 2. Gene microarray analysis: heatmap groups.
Symbol Description Fold Change
Group A WT+GW vs WT PDK1+GW vs WT
Acaca acetyl-Coenzyme A carboxylase alpha 3.4 3.0
Acss2 acyl-CoA synthetase short-chain family member 2 3.1 2.7
Acly ATP citrate lyase 3.8 2.5
Cspg3 chondroitin sulfate proteoglycan 3 4.4 4.1
Elovl6 ELOVL family member 6, elongation of long chain fatty acids (yeast) 3.5 3.7
Hspa9a heat shock protein 9A 3.3 2.7
Pdk4 pyruvate dehydrogenase kinase, isoenzyme 4 2.6 2.5
Slc2a5 solute carrier family 2 (facilitated glucose transporter), member 5 4.5 3.1
Tatdn1 TatD DNase domain containing 1 3.2 2.8
Group A9 WT+GW vs WT PDK1+GW vs WT
Asb5 ankyrin repeat and SOCs box-containing protein 5 21.3 21.7
Hrc histidine rich calcium binding protein 21.6 22.4
Mmd2 monocyte to macrophage differentiation-associated 2 22.0 21.7
Smpx small muscle protein, X-linked 21.8 23.6
Tcap titin-cap 22.3 25.5
Trdn triadin 24.5 23.7
Group B WT+GW vs WT PDK1 vs WT
Cox7a1 cytochrome c oxidase, subunit VIIa 1 5.3 3.7
Cpt1b carnitine palmitoyltransferase 1b, muscle 3.0 2.7
Elovl3 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3 18.2 9.4
Fabp3 fatty acid binding protein 3, muscle and heart 4.6 4.9
E2f5 E2F transcription factor 5 4.3 4.6
Slc27a2 solute carrier family 27 (fatty acid transporter), member 2 3.7 3.9
Ucp1 uncoupling protein 1 (mitochondrial, proton carrier) 6.5 4.6
Shown is the relative expression of metabolic genes common to GW510516-treated (GW) wild-type mice (WT), MMTV-PDK1 transgenic mice (PDK1) and GW501516-
treated MMTV-PDK1 mice (PDK1+GW) vs. WT. The heatmap groups refer to Figure S2A, and the gene expression profile of all groups is presented in Table S1.
doi:10.1371/journal.pone.0016215.t002
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normal glandular structure and ductal elongation and branching
at 3 and 12 weeks of age (Supporting information, Figure S1A).
Lactating transgenic mice exhibited strong PDK1 expression
(Supporting information, Figure S1B), but no delay in involution
vs. wild-type littermates (Supporting information, Figure S1C).
There were no differences between transgenic and wild-type mice
in their hyperplastic response to medroxyprogesterone stimulation,
and transgenic mice did not present with mammary tumors over
their lifespan (results not shown).
MMTV-PDK1 mice express increased levels of pT308AKT,
pS9 GSK3b and PPARd
IHC analysis of the mammary gland of 7 week-old pups
indicated increased pS241PDK1, pT308AKT and PPARd
expression vs. wild-type littermates (Figure 1B). Western analysis
revealed that increased PDK1 transgene expression was associated
with a 3–4-fold increase in pT308AKT and a 4–5.5-fold increase
in PPARd (Figure 1C), whereas, pS473AKT remained unaltered
(Figure 1C), as previously reported in PDK1 null cells [44]. The
levels of pS9GSK3b were increased 2.5–3.5-fold in transgenic
mice, but no changes were noted in PTEN, pmTOR, p4EBP1,
pS6 and pS657PKCa (Figure 1C). qRT-PCR analysis indicated
that PDK1 and PPARd mRNA levels were increased 3- and 1.4-
fold, respectively (results not shown) in comparison to the large
increases in protein expression, suggesting that their co-regulation
is in part due to post-translational regulation.
MMTV-PDK1 mice are sensitized to PPARd agonist
GW501516
Since MMTV-PDK1 mice did not present with mammary
tumors over their lifespan, they were tested for their susceptibility
to mammary carcinogenesis induced by progestin stimulation and
DMBA [40] (Figure 2A, B). MMTV-PDK1 mice did not exhibit a
statistically significant change in tumor latency, where median
tumor-free survival was 89 days vs. 110 days in wild-type mice
(Figure 2A). However, maintaining animals on a diet containing
the selective and potent PPARd agonist, GW501516, immediately
following DMBA, resulted in a dramatic acceleration of tumor
formation (Figure 2A). The tumor promoting effect of GW501516
was more pronounced in MMTV-PDK1 mice, where GW501516
treatment reduced the median tumor-free survival from 89 days to
21 days. This represented a two-fold greater reduction in survival
than observed in wild-type mice treated with GW501516, where
the median tumor-free survival was reduced from 110 days to 54
days (Figure 2B). Tumor multiplicity was similar in both groups
(1.88 and 1.40, respectively) and was not altered by GW501516
treatment (Table 1). Although there were no significant differences
in tumor histopathology between PDK1 and wild-type mice,
GW501516 treatment produced a significant increase in the
percentage of adenosquamous and squamous cell carcinomas in
both groups, which correlated with rapid tumor development
(Table 1).
Adenocarcinomas from MMTV-PDK1 mice express
increased pT308AKT and PPARd
HC analysis indicated that adenocarcinomas induced in
MMTV-PDK1 mice expressed elevated levels of PDK1,
pT308AKT and PPARd in comparison to histologically matched
tumors from wild-type mice (Figure 2C). Western analysis
confirmed that this phenotype was present in adenocarcinomas,
but not in squamous cell carcinomas from transgenic mice, as
might be expected from the mammary epithelium selectivity of the
MMTV promoter. However, no changes were evident in other
putative PDK1 downstream targets in either tumor histotype
(Figure 2D).
Figure 4. The metabolome of GW501516-treated wild-type and MMTV-PDK1 mice. Wild-type (WT) and MMTV-PDK1 (PDK1) mice were
maintained for 7 days on either standard or GW501516 (GW)-supplemented diets. The metabolite levels in mammary gland extracts were analyzed by
UPLC-ESI-TOFMS. The heatmaps depict the changes in negative ions for control and GW-treated WT and PDK1 mice in 6 replicate analyses.
doi:10.1371/journal.pone.0016215.g004
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To evaluate the effect of PPARd activation on PDK1 signaling,
mammary tissue was analyzed from wild-type and transgenic
animals maintained on the GW501516 diet (Figure 3A).
GW501516-treated wild-type mice expressed increased levels of
PDK1, pT308AKT and pS9GSK3b, whereas, transgenic mice
exhibited increased pT308AKT, but no additional changes in
PDK1 and pS9GSK3b, a result that we attribute to their already
elevated levels in the absence of GW501516 treatment. IHC
analysis of wild-type mice maintained on the GW501516 diet
confirmed increased levels of PDK1 and pT308AKT and PPARd,
and b-catenin although elevated, was primarily membrane-
associated and not nuclear (Figure 3B).
The causal association between PDK1 over-expression and
PPARd was also investigated in mouse mammary epithelial cell line
Comma-1D stably expressing PDK1 [43], which expresses high b-
catenin/TCF transcriptional activity [15]. Comma-1D/PDK1
cells, but not control cells exhibited increased levels of PPARd
(Figure 3C), and reporter gene assays in the presence and absence
of GW501516, as well as in the presence of dominant-negative
PPARd, confirmed that the receptor was transcriptionally active
(Figure 3D). Similar studies in HCT116 cells, which also express
PPARd and high b-catenin/TCF transcriptional activity confirmed
the dependence of both pathways on PDK1 (results not shown).
MMTV-PDK1 mice express a gene and metabolomic
profile reflecting PPARd activation
To further characterize the phenotype of MMTV-PDK1
mice and the effect of GW501516 treatment, gene expression
profiling was carried out with mammary tissue from
transgenic and wild-type mice maintained on the GW501516
diet for 1 week (Supporting information, Figure S2, Table
S1, Table S2). Hierarchical cluster analysis revealed changes
in gene expression that were specifically associated with
GW501516 treatment of both wild-type and transgenic
mice that were related to lipid (Acaca, Acly, Elovl6, Acss2) and
glucose (Acly, PDK4, Slc2a5) metabolism (Table 2, Group
A, Supporting information Figure S2A, Table S2), as well
as non-metabolic functions (Asb5, Hrc, Mmd2, Smpx, Tcap,
Trdn) (Table 2, Group A9, Supporting information Figure
S2A, Table S2). There was also an additional gene signature
common to MMTV-PDK1 and GW501516-treated wild-type
mice that was not associated with increased tumori
genesis (Cox7a1, Cpt1b, Elovl3, Fabp3, E2f5, Slcf5, Ucp1)
(Table 2, Group B, Supporting information Figure S2A, Table
S2).
Metabolomic analysis of the mammary gland revealed similar-
ities and differences between the metabolome of GW501516-
treated wild-type and transgenic animals, as well as between
control wild-type and transgenic mice. (Figure 4, Table 3,
Supporting information Figure S4, Table S3, Table S4, Table
S5). The suggestion of increased lipid biosynthesis based on gene
array data in GW501516-treated animals was consistent with
increased fatty acid and phospholipid levels, and correlated with
increased tumorigenesis (Table 3), despite the differences in
specific metabolites between the two groups. In contrast, untreated
transgenic mice exhibited a reduction in lipid metabolites vs. wild-
type mice.
Table 3. Metabolomic profile in MMTV-PDK1 and GW501516-treated animals.
MS Mass CQ_ID Name Fold Change Value
Algorithm
Identifer ESI
WT WT+GW
422.3301 cq_20090 Linoleyl carnitine 213.3 0.0041 0.0003 RF [M2H]
788.5236 cq_19896 Diarachidonoylphosphatidylethanolamine 41.0 0.0001 0.0023 SIMCA [M+H]
WT PDK1
216.0640 cq_00846 sn-Glycero-3-phosphoethanolamine 24.0 0.0017 0.0004 SIMCA [M+H]
280.2402303 cq_20055 Linoelaidic acid; 9E,12E-Octadecadienoic acid 22.3 0.0162 0.0071 RF [M+H]
388.2614 cq_10636 7a-Hydroxy-3-oxo-4-cholenoic acid 24.7 0.0021 0.0004 RF [M+H]
428.3725 cq_10816 Stearoylcarnitine 21.9 0.0116 0.0060 SIMCA [M+H]
450.2620 cq_18534 1–16:1-Lysophosphatidylethanolamine 26.7 0.0128 0.0019 SIMCA [M2H]
452.2787 cq_18660 1–16:0-Lysophosphatidylethanolamine 21.6 0.0443 0.0283 SIMCA [M2H]
478.2954 cq_18657 1–18:1-Lysophosphatidylethanolamine 26.0 0.0309 0.0052 SIMCA [M2H]
WT PDK1+GW
279.2328 cq_20055 Linoelaidic acid; 9E,12E-Octadecadienoic acid 4.4 0.0071 0.0313 RF [M2H]
303.2321 cq_17815 Arachidonic acid; Eicosatetraenoic acid 4.2 0.0080 0.0336 SIMCA [M2H]
303.2321 cq_17815 Arachidonic acid; Eicosatetraenoic acid 2.5 0.0108 0.0272 RF [M+H]
424.3413 cq_20090 Linoleyl carnitine 2.6 0.0041 0.0106 SIMCA [M+H]
450.2620 cq_18534 Palmitoleic acid; 9Z-Hexadecenoic acid 14.3 0.0003 0.0043 SIMCA [M2H]
450.2620 cq_18534 1–16:1-Lysophosphatidylethanolamine 12.1 0.0010 0.0117 SIMCA, RF [M2H]
454.2913 cq_18660 1–16:0-Lysophosphatidylethanolamine 2.0 0.0089 0.0178 SIMCA [M+H]
480.3073 cq_18657 1–18:1-Lysophosphatidylglycerol 2.5 0.0080 0.0202 SIMCA, RF [M+H]
507.2736 cq_18985 1–18:2-Lysophosphatidylglycerol 2.2 0.0034 0.0076 SIMCA [M2H]
RF, Random Forest.
doi:10.1371/journal.pone.0016215.t003
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The present study has examined the effect of PDK1 transgene
expression on mammary carcinogenesis, and how it impacts the
tumor promoting effects of PPARd activation. Although PDK1
transgenic mice did not exhibit changes in mammary gland
development, function and tumorigenicity, they were markedly
sensitive to GW501516 treatment, where median tumor-free
survival was reduced four-fold in comparison to a two-fold
reduction in GW501516-treated wild-type mice. This striking
effect correlated with an increase in a specific metabolic gene
signature indicative of glycolysis and fatty acid biosynthesis that
was not present in either control wild-type or transgenic mice
(Figure 5, Supporting information Figure S3). It is well-known that
human cancers exhibit a near ubiquitous expression of metabolic
genes [45] that is widely regarded to support high rates of
proliferation [46]. This phenotype is consistent with the acceler-
ation of mammary tumorigenesis by GW501516 [29], the increase
in fatty acid biosynthesis by GW501516 in muscle cells [47], and
our analysis of the mammary gland metabolome in GW501516-
treated animals. Some of these changes may be related to
increased AKT activation in GW501516-treated animals, since it
is an important regulator of glucose and lipid metabolism in both
normal and malignant cells, including breast cancer [48,49]. AKT
phosphorylates and activates ATP:citrate lyase (Acly) to promote
tumor growth [50], and loss of Acly counteracts AKT-driven
tumorigenesis [51]. In addition, the PPARd target gene, Pdk4,
[47,52] reduces the flux of pyruvate into the tricarboxylic acid
cycle, and Acss2, which increases the flux of lactate to acetylCoA,
were increased in GW501516-treated animals (Table 2, Figure 5).
These changes are consistent with the greater levels of fatty acid
and phospholipid metabolites in GW501516-treated transgenic
mice in comparison to treated wild-type mice (Table 3), suggesting
their involvement in enhanced tumorigenesis. This association is
also in agreement with the increase in serum lysophospholipids in
women with high grade ovarian cancer [53].
The lack of tumorigenicity of PDK1 transgene expression is in
agreement with previous studies that found PDK1 over-expression
per se was not oncogenic unless expressed in a heterozygous PTEN
background [54] or together with a growth factor receptor with
oncogenic potential, such as erbB2 [12]. The lack of change in
pmTOR, p4EBP1, pS6, pPKCa (Figure 1C) and pRSK (results
not shown) in mammary tissue from PDK1 transgenic mice is also
consistent with the lack of change in S6K and RSK activation
following treatment of PDK1 hypomorphic mice with insulin [10].
Thus, low residual levels of PDK1 appear to be sufficient for
mammary gland development and function and for downstream
signaling.
One seminal finding in our study was the increase in PPARd
expression in the transgenic mammary gland. PPARd expression is
induced by K-Ras via ERK activation [55], and although PDK1
has been reported to regulate MEK1/2 activation [56], ERK
activation remained unchanged in MMTV-PDK1 mice (results not
shown). Another possible mechanism is that increased pS9GSK3b
by AKT inhibits the ability of GSK3b to phosphorylate and
destabilize b-catenin by proteasomal degradation, and thus results
in enhanced transcription of TCF target genes, such as PPARd
[57]. However, no evidence of nuclear b-catenin accumulation was
noted in GW501516-treated wild-type animals despite increased
pT308AKT expression (Fig. 3C), suggesting other signaling
mechanisms. The changes in PPARd observed in transgenic mice
may also have resulted from post-translational stabilization against
Figure 5. Schematic of the regulation of glucose and fatty acid metabolism by PDK1 and PPARd. One mechanism depicted is that PPARd
upregulates PDK1 expression and activates AKT to inhibit GSK3b and increase b-catenin/TCF-dependent transcription; however, it is controversial
whether PPARd is a TCF target gene. Activation of PPARd by GW501516 in wild-type and MMTV-PDK1 mice upregulates the expression of genes
(highlighted in yellow) associated with glucose transport (Slc2a5), acetylCoA formation through acetylCoA (Acss32, Pdk4), and fatty acid biosynthesis
(Acaca, Elovl6). Genes associated with fatty acid transport and transcriptional regulation (Fabp3), formation of acetylCoA from citrate (Acly), fatty acid
transport (Cpt1b), CoA fatty acid esters (Slc27a2) and increased oxidative phosphorylation (Cox7a1 and Ucp1) are increased by GW501516 in wild-
type mice and in untreated PDK1 transgenic mice, but do not correlate with GW501516-induced tumorigenesis. HDAC, histone deacetylase; FA, fatty
acid; PDH, pyruvate dehydrogenase; inhibition.
doi:10.1371/journal.pone.0016215.g005
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supported by our results in PDK1-transduced mouse mammary
epithelial cells, which expressed increased PPARd and PPARd-
dependent reporter gene activity (Figure 3C). It is equally plausible
that endogenous PPARd ligands generated by fatty acid metabo-
lism serve as PPARd ligands [59] to increase expression post-
translationally. Lastly, the co-association of PDK1 and PPARd
noted in mammary tumors [29] may also have enhanced resistance
of the receptor to ubiquitination and degradation.
In addition to increased expression of PPARd in MMTV-PDK1
mice, PDK1 levels were increased by PPARd agonist GW501516
(Figure 3B). The mouse PDK1 locus contains a PPRE in an
upstream enhancer region [36], and deletion of PPARd resulted
in a 50% reduction in PDK1 mRNA and .80% decrease in
PDK1 protein expression [35]. This could result in a feed
forward mechanism resulting from the effect of PDK1 and PPARd
on each others expression, and could explain their synergism in
tumorigenesis.
Many of the genes whose expression increased more than 3-fold
in MMTV-PDK1 mice were associated with muscle architecture
or motor function, e.g. myosin, nebulin, troponin 1, tropomyosin
and titin. A recent study profiling gene expression in the
mammary gland side population also noted a muscle-specific
expression pattern [60]. Although the function of these genes in
non-myogenic cells is unknown, troponin 1 has been found to bind
ERRa, enhance its transcriptional activity [61] and regulate the
metabolic switch to oxidative phosphorylation [62]. Thus, the
expression of these genes may be a factor in the increase in fatty
acid transport and oxidation in muscle cells treated with
GW501516 [47].
In summary, PDK1 expression in the mammary gland was not
oncogenic, but accelerated tumor formation in conjunction with a
PPARd agonist. GW501516-enhanced tumorigenesis was associ-
ated with a distinct gene and metabolomic signature related to
glycolysis and fatty acid biosynthesis. These results suggest that
PDK1 and PPARd may drive tumorigenesis by enhancing energy
metabolism.
Supporting Information
Figure S1 (A) Whole mounts of the mammary gland at 3 and 12
weeks of age in founder 192. Upper panel, Magnification 56; lower
panel, Magnification 206. (B) Response of PDK1 transgenic mice
to lactation and involution. Western blot of PDK1 expression in
non-lactating transgenic mice (+(1) and +(2)) and in lactating mice
at day 1 (D1) and day 10 (D10) following forced involution by teat
sealing. (C) Lactation and involution in transgenic mice. H&E
stained sections were prepared on day 1 (D1), day 3 (D3), day 7
(D7) and day 10 (D10) of lactating wild-type (2) and transgenic (+)
mice following forced involution.
(DOC)
Figure S2 Gene expression profiling of the mammary gland
from MMTV-PDK1 and wild-type mice before and after
treatment with GW501516. (A) Gene expression in wild-type
(WT) and MMTV-PDK1 (PDK1) mice with and without
GW501516 treatment. Untreated MMTV-PDK1 mice expressed
a phenotype indicative of wild-type mice treated with GW501516.
A list of gene expression changes is included in Table S1. (B) qRT-
PCR and gene microarray analysis. Shown are the –fold changes
in mammary gene expression between MMTV-PDK1 mice
(PDK1), PDK1 mice treated with GW510516 (PDK1+GW), and
wild-type mice treated with GW501516 (WT+GW) relative to
untreated WT mice. Each experimental group is based on pooled
samples from five mice.
(DOC)
Figure S3 PLS-DA scores plots demonstrating clustering of the
metabolomic data. Five samples of each group, wild-type (WT),
MMTV-PDK1 (PDK1) and GW501516 (GW)-treated WT and
PDK1 mice were analyzed by UPLC-ESI-TOFMS and analyzed
as described under Materials and Methods. The plot of scores [t1]
and [t2] are weighted averages, and the points in the plot are the
individual observations of the data for (A) WT vs. PDK1 mice, (B)
WT vs. GW-treated WT mice, and (C) PDK1 vs. GW-treated
PDK1 mice. Observations near each other in the plot are similar
and observations far away from each other are dissimilar.
(DOC)
Figure S4 Gene ontology associated with the heatmap sub-
groups for MMTV-PDK1 and GW501516-treated mice. The
subgroups are listed in Table 2, genes showing a 3-fold or greater
changes are listed in Table S1, and gene ontology is listed in Table
S2.
(DOC)
Table S1 Gene microarray analysis of control and GW501516-
treated animals.
(XLS)
Table S2 Gene ontology of heatmap subgroups.
(XLS)
Table S3 Metabolites in the mammary gland of GW501516-
treated wild-type mice vs. wild-type mice.
(XLS)
Table S4 Metabolites in the mammary gland of MMTV-PDK1
mice vs. wild-type mice.
(XLS)
Table S5 Metabolites in the mammary gland of GW501516-
treated MMTV-PDK1 mice vs. wild-type mice.
(XLS)
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